Polymorphisms in Genes Encoding Metalloproteinase 9 and Lymphotoxin- Alpha can Influence Warfarin Treatment

Borges, Jessica Bassabi; Hirata, Thiago Dominguez Crespo; Cerda, Álvaro; Fajardo, Cristina Moreno; Cesar, Raony Cc; França, João Id; Santos, Jéssica Cristina dos; Wang, Hui-Tzu L; Castro, Lara Reinel de; Sampaio, Marcelo Ferraz; Hirata, Rosário Dc; Hirata, Mario H.

doi:10.4172/2153-0645.1000143

Cited by 4 publications

(11 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pharmacogenomics enables scientists to assess specific genetic variants that may be responsible for an individual’s particular drug response by identifying the particular genetic loci involved [21]. Whole-genome SNP profiling, haplotyping, multigene analysis, and gene expression studies using biochips or microarrays [22], [23] are recently used to study individual responses to drugs at various levels and could facilitate drug discovery and development [24].…”

Section: Determinants Of Interindividual Drug Responsesmentioning

confidence: 99%

Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine

Ahmed

Zhou

et al. 2016

Genomics, Proteomics &Amp; Bioinformatics

259

159

View full text Add to dashboard Cite

The interindividual genetic variations in drug metabolizing enzymes and transporters influence the efficacy and toxicity of numerous drugs. As a fundamental element in precision medicine, pharmacogenomics, the study of responses of individuals to medication based on their genomic information, enables the evaluation of some specific genetic variants responsible for an individual’s particular drug response. In this article, we review the contributions of genetic polymorphisms to major individual variations in drug pharmacotherapy, focusing specifically on the pharmacogenomics of phase-I drug metabolizing enzymes and transporters. Substantial frequency differences in key variants of drug metabolizing enzymes and transporters, as well as their possible functional consequences, have also been discussed across geographic regions. The current effort illustrates the common presence of variability in drug responses among individuals and across all geographic regions. This information will aid health-care professionals in prescribing the most appropriate treatment aimed at achieving the best possible beneficial outcomes while avoiding unwanted effects for a particular patient.

show abstract

Section: Determinants Of Interindividual Drug Responsesmentioning

confidence: 99%

Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine

Ahmed

Zhou

et al. 2016

Genomics, Proteomics &Amp; Bioinformatics

259

159

View full text Add to dashboard Cite

show abstract

“…Anticoagulant therapy has high efficacy and applicability in many pathologies and it has been used heavily lately. 1 , 2 For example, warfarin is known to be the most commonly used anticoagulant and has been used in clinical medicine for more than 40 years now. 3 It is an oral medication that works as a competitive inhibitor of vitamin K epoxide reductase complex 1 ( VKORC1 ) and reduces the regeneration of vitamin K, which is needed as a cofactor for the activation of several clotting factors (eg, II, VII, IX and X) and anticoagulant proteins (eg, S, C and Z).…”

Section: Introductionmentioning

confidence: 99%

“… 8 It has been proven that warfarin lower the risk of developing stroke by 64% in atrial fibrillation patients. 2 Other indications for warfarin use include: prophylaxis and treatment of arising pulmonary embolisms, venous thrombosis, ischemic stroke, myocardial infarction, valve prosthesis, intracardiac thrombus and other cardiovascular diseases. 2 , 6 , 8 …”

Section: Introductionmentioning

confidence: 99%

“…The dosage of warfarin has been shown to be influenced by many clinical factors including vitamin K usage, age, and clinical characteristics of the patient, comorbidities, concomitant drugs, diet, and genetics. 2 , 15 The genetic causes of warfarin response variation have been extensively studied over the past 2 decades. 2 Among these, variants in genes encoding warfarin target (eg, VKORC1 ) and genes encoding warfarin metabolism (eg, CYP2C9 ) were affected by time and dose to meet target INR in patients treated with warfarin.…”

Section: Introductionmentioning

confidence: 99%

“… 2 , 15 The genetic causes of warfarin response variation have been extensively studied over the past 2 decades. 2 Among these, variants in genes encoding warfarin target (eg, VKORC1 ) and genes encoding warfarin metabolism (eg, CYP2C9 ) were affected by time and dose to meet target INR in patients treated with warfarin. 16 Nonetheless, other genes (eg, CYP4F2 , epoxide hydrolase I ( EPHX1 ), gamma-glutamyl carboxylase ( GGCX ), calumenin ( CALU ) and CYP2C19 ) have also been studied in different ethnic groups.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Variants in CDHR3, CACNAC1, and LTA Genes Predisposing Sensitivity and Response to Warfarin in Patients with Cardiovascular Disease

Alghamdi¹,

AL-Eitan²,

Alkhatib³

et al. 2021

IJGM

View full text Add to dashboard Cite

Introduction Warfarin has been in use for more than 60 years; however, it has serious side effects including major bleeding. The high interpatient variability in the required dose impacts the sensitivity and responsiveness to warfarin in different patients. This study aims to assess the influence of CDHR3, CACNAC1 , and LTA gene polymorphisms on the variability of warfarin dose requirements and susceptibility to coronary heart disease in the Jordanian population. Methods This study was conducted in the anti-coagulation clinic in Queen Alia Heart Institute in Amman, with 212 patients in total. Three SNPs were genotyped within CDHR3 (rs10270308), CACNAC1 (rs216013), and LTA (rs1041981) genes. Results Our findings revealed that patients with LTA polymorphism are more prone to warfarin sensitivity than others. Furthermore, carriers of the LTA polymorphism needed a lower initial dose of warfarin and are associated with less variation in doses required to achieve target INR. Conclusion The current study could help in understanding the role of genetic variability in warfarin dosing and matching patients to different treatment options. Clinical applications of these findings for warfarin treatment may also contribute to improving the efficacy and safety of warfarin treatment in Jordanian patients with cardiovascular disease.

show abstract

Cardiovascular Pharmacogenomics: An Update on Clinical Studies of Antithrombotic Drugs in Brazilian Patients

et al. 2021

View full text Add to dashboard Cite

Polymorphisms in Genes Encoding Metalloproteinase 9 and Lymphotoxin- Alpha can Influence Warfarin Treatment

Cited by 4 publications

References 39 publications

Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine

Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine

Variants in CDHR3, CACNAC1, and LTA Genes Predisposing Sensitivity and Response to Warfarin in Patients with Cardiovascular Disease

Cardiovascular Pharmacogenomics: An Update on Clinical Studies of Antithrombotic Drugs in Brazilian Patients

Contact Info

Product

Resources

About